At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Level of Expression and Prognostic Value of CXCL4, CXCL4L1 and CXCR3 in Renal Cell Carcinoma
In Brief
An observational study evaluating Biological sample for Carcinoma and 4 related conditions. Completed, enrolled 310 participants across 1 site.
Detailed Summary
Despite novel treatment options, Renal Cell Carcinoma (RCC) has been characterized by a constant increase in its mortality and consequently requires an important involvement in translational research. The aim of this study is to evaluate the interest of CXCL4, CXCL4L1 and CXCR3 as biomarkers in localized, locally advanced or metastatic RCC. Indeed these chemokines have shown anti-angiogenic and anti-tumor properties in experimental models and may be particularly interesting for prognostic and predictive purposes.
Study Details
Timeline
Interventions
2 blood samples of 10mL + one urine sample * on pre-operative d-1/d, post-operative d1 and d5(+/-2), * one month post-operative, * at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises.
2 blood samples of 10mL + one urine sample * before starting the therapy * at first therapeutic evaluation (2 or 3 months depending on the treatment chosen) * at the end of the study or at the date of disease progression.